Subscribe to Updates for A Study to See Iftolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old withAutosomal Recessive Polycystic Kidney Disease (ARPKD)

Stay informed about the latest developments in this trial. By subscribing, you will receive updates directly to your email. These updates will provide you with important information regarding any changes or progress related to the trial.